Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1045 results
February 2015
-
Media ReleaseNovartis receives FDA approval of Farydak®, the first HDAC inhibitor for patients with multiple myelomaFarydak, an HDAC inhibitor with epigenetic activity, approved in combination for patients who received at least two prior regimens including bortezomib and IMiD[1] Farydak prolonged median…
-
Media ReleaseNovartis' heart failure medicine LCZ696 granted FDA priority reviewDecision could speed access to LCZ696 for HFrEF patients in the US, reducing total review time from 12 to 8 months Filing is based on results from the landmark PARADIGM-HF study[1] …
-
Media ReleaseAlcon receives FDA approval of Pazeo(TM) Solution for ocular allergy itch reliefUS Food and Drug Administration grants approval of Pazeo(TM) (olopatadine hydrochloride ophthalmic solution) 0.7% for sale in the United States Developed with efficacy data at 24 hours, post dose…
January 2015
-
Media ReleaseNovartis announces study in NEJM showing Jakavi® was superior to standard therapy in rare blood cancer polycythemia veraJakavi® (ruxolitinib) treatment resulted in durable hematocrit control, spleen size reduction and symptom relief for patients with uncontrolled polycythemia vera[1] Polycythemia vera (PV) is…
-
Media ReleaseNovartis delivered solid sales growth, margin expansion and pipeline progress in 2014; portfolio transformation will focus company on leading businessesNet sales grew in FY 2014, with strong core[1] margin expansion Net sales increased 1% (+3% cc[1])[2] to USD 58.0 billion in FY (Q4: -2%, +4% cc) Operating income grew 1% (+7% cc) to USD 10.7…
-
Media ReleaseNovartis Bexsero® vaccine approved by FDA for the prevention of meningitis B, a leading cause of bacterial meningitis in the USWith today's approval, Bexsero is now licensed in 37 countries; since first approval in Europe, over 1 million doses have been distributed worldwide Bexsero's two-dose regimen offers a flexible…
-
Media ReleaseNovartis drug Jakavi® recommended by CHMP for EU approval to treat adults with rare blood cancer polycythemia veraPolycythemia vera (PV) is associated with overproduction of blood cells that can cause serious cardiovascular complications, such as stroke and heart attack[1] Clinical data show Jakavi® (…
-
Media ReleaseNovartis announces FDA approval for first IL-17A antagonist Cosentyx(TM) (secukinumab) for moderate-to-severe plaque psoriasis patientsOffering a new treatment option for patients, Cosentyx is the first approved human monoclonal antibody (mAb) that selectively binds to interleukin IL-17A[1],[2] Phase III data demonstrated…
-
Media ReleaseNovartis Cosentyx(TM) is the first IL-17 inhibitor to receive EU approval for first-line treatment of moderate-to-severe psoriasis patientsCosentyx is the only biologic that can be used as first-line systemic therapy in the treatment of psoriasis and as an alternative to treatments that have significant side effects[1]; all other…
-
Media ReleaseNovartis Pharmaceuticals announces a joint investment company with Qualcomm, leading innovation in digital medicines for physicians and patientsNovartis establishing a joint investment company with Qualcomm Ventures, the venture investment group of Qualcomm Incorporated, of up to USD 100 million to support early stage companies with…
-
Media ReleaseNovartis announces robust Phase III results for QVA149 and NVA237 and submits regulatory applications to US FDAPivotal Phase III results for QVA149 and NVA237 met their primary endpoints and significantly improved lung function in COPD patients[1-5] US trials for QVA149 demonstrated significant…
-
Media ReleaseSandoz biosimilar filgrastim recommended for approval by FDA Oncologic Drugs Advisory CommitteeOncologic Drugs Advisory Committee (ODAC) votes in favor of recommending biosimilar filgrastim for approval in the US Biosimilar filgrastim recommended to be approved for use in all requested…
Pagination
- ‹ Previous page
- 1
- …
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- › Next page